Patent infringement claim dismissed because generic escitalopram sale did not violate the specific method patent rights.

The court dismissed Rekvisitus A/S's claim that selling generic escitalopram infringed Rekvirent A/S's method patent. Rekvisitus argued its sales violated the patent, while Rekvirent contended the method claims covered the generic product's production. The court ruled that selling the finished generic drug did not constitute an infringement of the method patent rights held by Rekvirent.